Myogem presents the results of preclinical studies of the MyoDM food supplement in preclinical models of T1DM at the International Congress on Myotonic Dystrophy (IDMC-12), held in Gothenburg, Sweden, from June 10 to 14, 2019.
In two interesting results of MyoDM in animal models of Myotonic Dystrophy, statistically significant improvements in the therapeutic effect were observed based on the increase in MBNL1 expression levels when administering MyoDM. These results can be seen in the presented poster entitled “Natural xanthines caffeine and theobromine rescue myotonic dystrophy-like features in cell and animal models.”
